Cohance Lifesciences Limited (NSE:COHANCE)
India · Delayed Price · Currency is INR 324.50
+15.75 (5.10%)
Feb 18, 2026, 3:29 PM IST
Cohance Lifesciences Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Net Income | 2,679 | 3,003 | 4,113 | 4,538 | 3,623 |
Depreciation & Amortization | 774.9 | 546 | 464.6 | 390.22 | 316.89 |
Other Amortization | - | - | - | 3.91 | 3.85 |
Loss (Gain) From Sale of Assets | 1.1 | 0.7 | 0.07 | -0.01 | -0.34 |
Loss (Gain) From Sale of Investments | -400.3 | -449.1 | -156.87 | -82.03 | -33.28 |
Stock-Based Compensation | 149.2 | 19.7 | - | - | - |
Other Operating Activities | -0.6 | 8.5 | 93.58 | 389.52 | 36.65 |
Change in Accounts Receivable | -1,480 | 128.2 | 1,245 | -1,361 | 133.61 |
Change in Inventory | 741.2 | 816.1 | -293.93 | -823.37 | -262.08 |
Change in Accounts Payable | 417 | -225.2 | -357.99 | 232.04 | 119.45 |
Change in Other Net Operating Assets | - | - | -535.05 | 12.55 | -112.71 |
Operating Cash Flow | 2,882 | 3,848 | 4,572 | 3,300 | 3,825 |
Operating Cash Flow Growth | -25.11% | -15.84% | 38.54% | -13.74% | -5.99% |
Capital Expenditures | -1,557 | -518.8 | -2,859 | -751.87 | -1,108 |
Sale of Property, Plant & Equipment | - | - | 0.72 | 0.01 | 0.34 |
Cash Acquisitions | -7,280 | - | - | - | - |
Investment in Securities | 6,234 | -3,101 | 844.55 | -560.72 | -2,005 |
Other Investing Activities | 50.1 | -4.2 | 63.79 | -48.8 | -0.54 |
Investing Cash Flow | -2,553 | -3,624 | -1,950 | -1,361 | -3,114 |
Short-Term Debt Issued | 246.4 | - | - | - | 123.02 |
Long-Term Debt Issued | - | - | - | - | 8.91 |
Total Debt Issued | 246.4 | - | - | - | 131.93 |
Short-Term Debt Repaid | - | -270.4 | -26.11 | -385.66 | - |
Long-Term Debt Repaid | -108.9 | -60 | -241.33 | -98.58 | -547.27 |
Total Debt Repaid | -108.9 | -330.4 | -267.43 | -484.24 | -547.27 |
Net Debt Issued (Repaid) | 137.5 | -330.4 | -267.43 | -484.24 | -415.34 |
Common Dividends Paid | - | - | -2,037 | -1,018 | -254.57 |
Other Financing Activities | -104.3 | -69.5 | -115.56 | -62.31 | -86.72 |
Financing Cash Flow | 33.2 | -399.9 | -2,420 | -1,565 | -756.62 |
Foreign Exchange Rate Adjustments | 19.9 | - | - | 0 | 0 |
Miscellaneous Cash Flow Adjustments | - | - | - | - | 0 |
Net Cash Flow | 381.7 | -175.7 | 202.39 | 373.82 | -45.13 |
Free Cash Flow | 1,325 | 3,329 | 1,713 | 2,548 | 2,717 |
Free Cash Flow Growth | -60.21% | 94.35% | -32.78% | -6.21% | -10.58% |
Free Cash Flow Margin | 11.06% | 31.66% | 12.78% | 19.30% | 26.91% |
Free Cash Flow Per Share | 5.18 | 13.08 | 6.73 | 10.01 | 10.67 |
Cash Interest Paid | 104.3 | 69.5 | 115.56 | 62.31 | 89.24 |
Cash Income Tax Paid | 834.4 | 1,100 | 1,458 | 1,843 | 1,094 |
Levered Free Cash Flow | 1,429 | 2,967 | 1,079 | 1,027 | 1,511 |
Unlevered Free Cash Flow | 1,506 | 3,014 | 1,159 | 1,066 | 1,568 |
Change in Working Capital | -321.4 | 719.1 | 57.68 | -1,940 | -121.73 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.